Publications by authors named "F Veber"
Objectives: Although widely recommended, data on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) efficacy in HIV-1-infected children/adolescents are mainly extrapolated from studies in adults and one paediatric trial in which subjects have good treatment adherence. This study aimed to provide data about the risk of virological failure (VF) and acquired genotypic resistance in children and adolescents receiving BIC/FTC/TAF in a real-world setting.
Methods: This retrospective monocentric study included 74 paediatric patients who received BIC/FTC/TAF during ≥6 months in 2019-2023.
Objectives: Increased weight gain with dolutegravir use is increasingly scrutinized in adults, but published data in paediatrics are limited and conflicting. This study aimed to provide long-term data about changes in body mass index (BMI) in French children (aged 3-9 years) and adolescents (aged 10-17 years) receiving dolutegravir.
Patients And Methods: This retrospective monocentric study included 97 subjects who received a dolutegravir-based regimen for ≥12 months in 2014-2021.
Objectives: Although widely recommended, data about dolutegravir efficacy in HIV-1-infected children/adolescents are scarce, limited to short-term follow-up and mainly extrapolated from studies in adults with good adherence to treatment. This study aimed to provide long-term data about the risk of virological failure (VF) and acquired genotypic resistance in children and adolescents receiving dolutegravir.
Methods: This retrospective monocentric study included 134 paediatric patients who received a dolutegravir-based regimen for ≥ 12 months in 2014-2020.
Article Synopsis
- Early initiation of antiretroviral therapy (ART) in HIV-1-infected infants shows a positive impact on immune system health, specifically CD4 and CD8 T lymphocytes, but the effects in older children and adolescents need more study.
- The ANRS-EP59-CLEAC study examined 27 children and 9 adolescents who started ART early compared to 19 children and 21 adolescents who started later, revealing that early treatment leads to higher CD8 T cell percentages.
- Overall, while early ART benefits CD8 T cells significantly, the impact on CD4 T cells is less pronounced, suggesting late-treated pediatric patients can still effectively counteract CD4 T-cell loss through thymus production.
Article Synopsis
- The study evaluated the health outcomes of 163 HIV-infected children and adolescents at a major pediatric HIV center in France during 2016-2017, focusing on their antiretroviral treatment and viral load suppression rates compared to UNAIDS targets.
- Most participants were from Sub-Saharan Africa or France, with a high antiretroviral coverage of 98.2%, and a significant number (80.3%) achieved virological suppression, despite some showing resistance to HIV medications.
- The findings indicate that the high rate of treatment coverage and viral load suppression surpasses the second UNAIDS target and is nearing the third target for virological suppression among children in high-income settings.